Peter Moldt

Peter Moldt is a Partner in Novo Ventures, Novo A/S.

Peter Moldt joined Novo A/S in 2009. He is a member of the board of directors of HemoFocus ApS and Neurokey A/S.

In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development.

Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University’s Department of Organic Chemistry.